*** Bristol-Myers Shareholders Vote In Favor Of $74B Celgene Acquisition

*** Bristol-Celgene Combination Creates Cancer Drug Powerhouse With Nearly $38 billion in Yearly Sales

*** Bristol-Myers Approval For Celgene Follows Unsuccessful Activist Campaign to Undo Deal

(END) Dow Jones Newswires

April 12, 2019 10:49 ET (14:49 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Mär 2024 bis Apr 2024 Click Here for more Bristol Myers Squibb Charts.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Apr 2023 bis Apr 2024 Click Here for more Bristol Myers Squibb Charts.